Literature DB >> 17382798

The atypical urothelial cancer patient: management of bladder cancers of non-transitional cell histology and cancers of the ureters and renal pelvis.

Timothy Gilligan1, Robert Dreicer.   

Abstract

Non-transitional cell neoplasms of the bladder and upper tract transitional cell carcinomas (ureter and renal pelvis) represent only a small fraction of urothelial carcinomas. Clinicians faced with the rare case are always confronted with management dilemmas complicated by the scarcity of published experience to guide decisions. The current review brings together the best of the limited published data in an attempt to provide some reasonable context to help in the management of these difficult neoplasms.

Entities:  

Mesh:

Year:  2007        PMID: 17382798     DOI: 10.1053/j.seminoncol.2006.12.005

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  4 in total

1.  FDG-PET/CT-guided biopsy of bone metastases sets a new course in patient management after extensive imaging and multiple futile biopsies.

Authors:  M K Werner; P Aschoff; M Reimold; C Pfannenberg
Journal:  Br J Radiol       Date:  2011-03       Impact factor: 3.039

2.  The WHO ultrasonography protocol for assessing morbidity due to Schistosoma haematobium. Acceptance and evolution over 14 years. Systematic review.

Authors:  Robert Akpata; Andreas Neumayr; Martha C Holtfreter; Ingela Krantz; Daman D Singh; Rodrigo Mota; Susanne Walter; Christoph Hatz; Joachim Richter
Journal:  Parasitol Res       Date:  2015-02-25       Impact factor: 2.289

Review 3.  Adenocarcinoma of the urinary bladder.

Authors:  Vipulkumar Dadhania; Bogdan Czerniak; Charles C Guo
Journal:  Am J Clin Exp Urol       Date:  2015-08-08

4.  Response to Anti-HER2-Based Treatment in a Patient with Bladder Adenocarcinoma Harboring HER2 Amplification and S310F Mutation Discovered by Next-Generation Sequencing: A Case Report.

Authors:  Xiaolu Wang; Wenjing Hu; Li Xie
Journal:  Onco Targets Ther       Date:  2020-05-18       Impact factor: 4.147

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.